Ftse Mib
37.698,31
-1,38%
DAX
22.328,77
-1,23%
S&P 500
5.572,07
-0,76%
NASDAQ
17.436,10
-0,18%
Bitcoin
83.143,83
0,35%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Germania TG Biogen Inc (IDP) Biogen Inc (IDP) Notizie

Biogen Inc

IDP
131,65
-7,70 (-5,53%)
11 Mar 2025 - Chiuso
Dati in Tempo Reale
Borsa: Tradegate
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
11/3/202512:30UKREGBiogen Initiates Phase 3 Study of Felzartamab for the..
18/2/202514:00UKREGBiogen and Stoke Therapeutics Enter into Collaboration to..
31/1/202512:30UKREGUpdate on Regulatory Review of Lecanemab for Early..
27/1/202500:33UKREGFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing..
23/1/202513:30UKREGFDA and EMA Accept Applications for Higher Dose Regimen of..
14/1/202501:05UKREGFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License..
19/11/202407:00UKREGDapirolizumab Pegol Phase 3 Data Presented at the American..
14/11/202417:23UKREGEisai Receives Positive Opinion from the CHMP in the..
31/10/202400:30UKREGEisai Presents Data on Benefits of Long-Term Administration..
29/10/202423:00UKREGBiogen and Neomorph Announce Multi-Target Research..
29/10/202413:00UKREGBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer
28/10/202413:30UKREGMichael McDonnell, Executive Vice President and Chief..
27/10/202402:15UKREGBiogen Presents Positive Results from Phase 2 IGNAZ Study of..
24/10/202413:30UKREGBiogen to Present New Data at the Clinical Trials on..
22/10/202413:30UKREGBiogen Announces Late Breaker and New Data Presentations at..
09/10/202413:30UKREGBiogen Receives U.S. FDA Breakthrough Therapy Designation..
08/10/202413:30UKREGNew Higher Dose Nusinersen Efficacy and Safety Data..
24/9/202407:00UKREGUCB and Biogen Announce Positive Topline Results From Phase..
12/9/202413:30UKREGBiogen Board Appoints Two New Independent Directors
04/9/202413:30UKREGBiogen Announces Positive Topline Results from Study of..
30/7/202423:15UKREGNew Clinical Data Demonstrates Three Years of Continuous..
30/7/202413:30UKREGBiogen, Beckman Coulter and Fujirebio to Collaborate on..
26/7/202413:20UKREGUpdate on Regulatory Review of Lecanemab for Early..
02/7/202415:16GLOBEBiogen Completes Acquisition of Human Immunology Biosciences
28/6/202401:39GLOBE“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s..
24/6/202413:30GLOBETOFIDENCE™ (tocilizumab), a Biosimilar Referencing..
10/6/202401:37GLOBEFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb)..
30/5/202422:51GLOBEBiogen Receives European Commission Approval for..
22/5/202413:30GLOBEBiogen Bolsters Late-Stage Pipeline, Expands Immunology..
16/5/202413:30GLOBEBiogen and Ionis Announce Topline Phase 1/2 Study Results of..
15/5/202401:33GLOBEEisai Initiates Rolling Biologics License Application to US..
25/4/202422:05GLOBEBiogen Receives Positive CHMP Opinion for TOFIDENCE™..
Apertura: 139,00 Min: 130,20 Max: 140,10
Chiusura: 139,35

La tua Cronologia

TG
IDP
Biogen
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci